tracken
MediWound Ltd. Aktie News
Neutral
Seeking Alpha
●
2 Tage alt
MediWound Ltd. ( MDWD ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Joshua Jennings - TD Cowen, Research Division Swayampakula Ramakanth - H.C.
Neutral
GlobeNewsWire
●
2 Tage alt
Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid ® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Million Equity Financing Third Quarter 2025 Revenue of $5.4 Million, Up 23% Year-over-Year Conference Call Today, November 20, 2025, at 8:30 a.m. Eastern Time YAV...
Neutral
GlobeNewsWire
●
17 Tage alt
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd.
Neutral
GlobeNewsWire
●
19 Tage alt
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid ®
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
MediWound Expands Global Reach with Marketing Approval of NexoBrid ® in Australia
Neutral
GlobeNewsWire
●
3 Monate alt
MediWound's NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin,...
Positiv
Seeking Alpha
●
3 Monate alt
MediWound is a niche biotech with strong R&D, FDA-approved products, and a promising pipeline, but remains underfollowed and volatile. Despite weak current performance and negative metrics, the company has a solid cash runway, no debt, and recent strategic investments. NexoBrid's expanded approvals and rising hospital orders, plus a new facility, position MediWound for significant revenue growt...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
